$ABUS
Arbutus Biopharma Corp Stock $abus

$abus Overview Financials Valuation SEC Filings Company Website

2016 Q1 Form 10-K Financial Statement

#000162828016012462 Filed on March 09, 2016

Income Statement

Concept	2016 Q1	2014 Q4	2014 Q3
Revenue	$603.0K	$4.350M	$4.362M
YoY Change	-87.12%	-40.33%	47.36%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$7.220M	$3.080M	$1.760M
YoY Change	165.44%	11.59%	83.33%
% of Gross Profit
Research & Development	$13.14M	$11.90M	$9.310M
YoY Change	24.51%	81.96%	68.97%
% of Gross Profit
Depreciation & Amortization	$217.0K	$110.0K	$140.0K
YoY Change	80.83%	-21.43%	-6.67%
% of Gross Profit
Operating Expenses	$20.58M	$15.10M	$11.21M
YoY Change	-9.29%	60.13%	69.59%
Operating Profit	-$19.98M	-$10.75M	-$6.844M
YoY Change	10.95%
Interest Expense	$0.00	$5.040M	-$1.760M
YoY Change	-100.0%	-4681.82%	-21.78%
% of Operating Profit
Other Income/Expense, Net	$4.103M
YoY Change	-31.81%
Pretax Income	-$15.87M	-$6.170M	-$8.600M
YoY Change	32.36%	174.22%	45.52%
Income Tax		$0.00	$0.00
% Of Pretax Income
Net Earnings	-$15.87M	-$6.168M	-$8.604M
YoY Change	32.4%	174.13%	45.58%
Net Earnings / Revenue	-2632.5%	-141.79%	-197.25%
Basic Earnings Per Share
Diluted Earnings Per Share	-$308.8K	-$275.9K	-$388.1K
COMMON SHARES
Basic Shares Outstanding	54.63M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2016 Q1	2014 Q4	2014 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$172.6M	$112.2M	$108.8M
YoY Change	-25.7%	63.32%	203.91%
Cash & Equivalents	$144.8M	$72.19M	$78.20M
Short-Term Investments	$27.80M	$40.00M	$30.60M
Other Short-Term Assets	$1.500M	$1.700M	$700.0K
YoY Change	15.38%	30.77%	-36.36%
Inventory
Prepaid Expenses
Receivables	$340.0K	$1.903M	$2.200M
Other Receivables	$200.0K	$100.0K	$100.0K
Total Short-Term Assets	$174.8M	$116.4M	$111.7M
YoY Change	-27.12%	65.6%	165.95%
LONG-TERM ASSETS
Property, Plant & Equipment	$3.242M	$1.760M	$1.600M
YoY Change	80.11%	25.71%	14.29%
Goodwill	$162.5M	$0.00
YoY Change
Intangibles	$352.6M	$0.00
YoY Change
Long-Term Investments	$10.10M		$11.70M
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$528.5M	$1.760M	$13.40M
YoY Change	-3.44%	25.71%	857.14%
TOTAL ASSETS
Total Short-Term Assets	$174.8M	$116.4M	$111.7M
Total Long-Term Assets	$528.5M	$1.760M	$13.40M
Total Assets	$703.3M	$118.2M	$125.1M
YoY Change	-10.65%	64.82%	188.25%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$4.000M	$2.000M	$3.400M
YoY Change	-44.44%	66.67%	325.0%
Accrued Expenses	$3.400M	$7.000M	$2.400M
YoY Change	-46.88%	191.67%	-31.43%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$11.11M	$20.21M	$19.50M
YoY Change	-55.37%	61.65%	43.38%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$7.700M	$9.900M	$10.10M
YoY Change	-38.89%
Total Long-Term Liabilities	$7.700M	$9.900M	$10.10M
YoY Change	-38.89%
TOTAL LIABILITIES
Total Short-Term Liabilities	$11.11M	$20.21M	$19.50M
Total Long-Term Liabilities	$7.700M	$9.900M	$10.10M
Total Liabilities	$165.2M	$30.14M	$29.60M
YoY Change	-14.59%	141.14%	117.65%
SHAREHOLDERS EQUITY
Retained Earnings	-$282.9M	-$205.9M
YoY Change
Common Stock	$840.5M	$290.0M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$538.1M	$88.04M	$95.50M
YoY Change
Total Liabilities & Shareholders Equity	$703.3M	$118.2M	$125.1M
YoY Change	-10.65%	64.82%	188.25%

Cashflow Statement

Concept	2016 Q1	2014 Q4	2014 Q3
OPERATING ACTIVITIES
Net Income	-$15.87M	-$6.168M	-$8.604M
YoY Change	32.4%	174.13%	45.58%
Depreciation, Depletion And Amortization	$217.0K	$110.0K	$140.0K
YoY Change	80.83%	-21.43%	-6.67%
Cash From Operating Activities	-$11.55M	-$6.840M	-$6.730M
YoY Change	-35.29%	-367.19%	83.38%
INVESTING ACTIVITIES
Capital Expenditures	$276.0K	-$330.0K	-$150.0K
YoY Change	95.74%	65.0%	25.0%
Acquisitions
YoY Change
Other Investing Activities	-$13.31M	$1.380M	-$290.0K
YoY Change	-135.31%
Cash From Investing Activities	-$13.58M	$1.060M	-$450.0K
YoY Change	-136.17%	-630.0%	275.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$0.00
YoY Change	-100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$115.0K	470.0K	690.0K
YoY Change	-99.92%	-98.55%	885.71%
NET CHANGE
Cash From Operating Activities	-$11.55M	-6.840M	-6.730M
Cash From Investing Activities	-$13.58M	1.060M	-450.0K
Cash From Financing Activities	$115.0K	470.0K	690.0K
Net Change In Cash	-$25.01M	-5.310M	-6.490M
YoY Change	-115.39%	-115.26%	74.46%
FREE CASH FLOW
Cash From Operating Activities	-$11.55M	-$6.840M	-$6.730M
Capital Expenditures	$276.0K	-$330.0K	-$150.0K
Free Cash Flow	-$11.82M	-$6.510M	-$6.580M
YoY Change	-34.26%	-335.87%	85.35%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2014Q4	abus	Accrued License Fee Current AccruedLicenseFeeCurrent	250000	USD
CY2015Q4	abus	Accrued License Fee Current AccruedLicenseFeeCurrent	0	USD
CY2014Q4	abus	Accrued Payroll Current AccruedPayrollCurrent	2873000	USD
CY2015Q4	abus	Accrued Payroll Current AccruedPayrollCurrent	2331000	USD
CY2014Q4	abus	Accrued Researchand Development Current AccruedResearchandDevelopmentCurrent	2391000	USD
CY2015Q4	abus	Accrued Researchand Development Current AccruedResearchandDevelopmentCurrent	2358000	USD
CY2013	abus	Balance Weightedaverageremainingcontractuallife BalanceWeightedaverageremainingcontractuallife	P2Y8M12D
CY2014	abus	Balance Weightedaverageremainingcontractuallife BalanceWeightedaverageremainingcontractuallife	P1Y9M18D
CY2015	abus	Balance Weightedaverageremainingcontractuallife BalanceWeightedaverageremainingcontractuallife	P9M18D
CY2014	abus	Business Acquisition Pro Forma Earnings Loss Per Share Basic And Diluted BusinessAcquisitionProFormaEarningsLossPerShareBasicAndDiluted	-1.24
CY2015	abus	Business Acquisition Pro Forma Earnings Loss Per Share Basic And Diluted BusinessAcquisitionProFormaEarningsLossPerShareBasicAndDiluted	-1.38
CY2015Q3	abus	Business Combination Acceleration Of Share Based Compensation Expense Per Quarter BusinessCombinationAccelerationOfShareBasedCompensationExpensePerQuarter	1900000	USD
CY2014	abus	Class Of Warrant Or Right Exercised During Period ClassOfWarrantOrRightExercisedDuringPeriod	616478	shares
CY2015	abus	Class Of Warrant Or Right Exercised During Period ClassOfWarrantOrRightExercisedDuringPeriod	18750	shares
CY2014	abus	Class Of Warrant Or Right Exercised During Period Exercise Price ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice	3.09
CY2014	abus	Class Of Warrant Or Right Exercised During Period Exercise Price ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice	2.80
CY2015	abus	Class Of Warrant Or Right Exercised During Period Exercise Price ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice	2.25
CY2015	abus	Class Of Warrant Or Right Exercised During Period Exercise Price ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice	2.88
CY2013	abus	Class Of Warrant Or Right Price Of Warrants Or Rights Intrinsic Value ClassOfWarrantOrRightPriceOfWarrantsOrRightsIntrinsicValue	5298000	USD
CY2013	abus	Class Of Warrant Or Right Price Of Warrants Or Rights Intrinsic Value ClassOfWarrantOrRightPriceOfWarrantsOrRightsIntrinsicValue	5635000	CAD
CY2014	abus	Class Of Warrant Or Right Price Of Warrants Or Rights Intrinsic Value ClassOfWarrantOrRightPriceOfWarrantsOrRightsIntrinsicValue	5343000	USD
CY2014	abus	Class Of Warrant Or Right Price Of Warrants Or Rights Intrinsic Value ClassOfWarrantOrRightPriceOfWarrantsOrRightsIntrinsicValue	5902000	CAD
CY2015	abus	Class Of Warrant Or Right Price Of Warrants Or Rights Intrinsic Value ClassOfWarrantOrRightPriceOfWarrantsOrRightsIntrinsicValue	879000	USD
CY2015	abus	Class Of Warrant Or Right Price Of Warrants Or Rights Intrinsic Value ClassOfWarrantOrRightPriceOfWarrantsOrRightsIntrinsicValue	1217000	CAD
CY2015	abus	Cumulative Contributionfor Product CumulativeContributionforProduct	3702000	CAD
CY2015	abus	Cumulative Contributionfor Product CumulativeContributionforProduct	2675000	USD
CY2014Q4	abus	Deferred Tax Asset Book Amortization In Excess Of Tax DeferredTaxAssetBookAmortizationInExcessOfTax	2745000	USD
CY2015Q4	abus	Deferred Tax Asset Book Amortization In Excess Of Tax DeferredTaxAssetBookAmortizationInExcessOfTax	2142000	USD
CY2014Q4	abus	Deferred Tax Asset Revenue Recognized For Tax Purposes In Excess Of Revenue Recognized For Accounting Purposes DeferredTaxAssetRevenueRecognizedForTaxPurposesInExcessOfRevenueRecognizedForAccountingPurposes	4086000	USD
CY2015Q4	abus	Deferred Tax Asset Revenue Recognized For Tax Purposes In Excess Of Revenue Recognized For Accounting Purposes DeferredTaxAssetRevenueRecognizedForTaxPurposesInExcessOfRevenueRecognizedForAccountingPurposes	281000	USD
CY2014Q4	abus	Deferred Tax Asset Tax Value In Excess Of Accounting Value In Lease Inducements DeferredTaxAssetTaxValueInExcessOfAccountingValueInLeaseInducements	65000	USD
CY2015Q4	abus	Deferred Tax Asset Tax Value In Excess Of Accounting Value In Lease Inducements DeferredTaxAssetTaxValueInExcessOfAccountingValueInLeaseInducements	77000	USD
CY2014Q4	abus	Deferred Tax Asset Upfront License Fees DeferredTaxAssetUpfrontLicenseFees	0	USD
CY2015Q4	abus	Deferred Tax Asset Upfront License Fees DeferredTaxAssetUpfrontLicenseFees	629000	USD
CY2013	abus	Fair Value Of Warrants Exercised In The Period FairValueOfWarrantsExercisedInThePeriod	1854000	USD
CY2014	abus	Fair Value Of Warrants Exercised In The Period FairValueOfWarrantsExercisedInThePeriod	10208000	USD
CY2015	abus	Fair Value Of Warrants Exercised In The Period FairValueOfWarrantsExercisedInThePeriod	334000	USD
CY2013	abus	Fair Value Of Warrants Exercised On A Cashless Basis FairValueOfWarrantsExercisedOnACashlessBasis	1404000	USD
CY2014	abus	Fair Value Of Warrants Exercised On A Cashless Basis FairValueOfWarrantsExercisedOnACashlessBasis	-116000	USD
CY2015	abus	Fair Value Of Warrants Exercised On A Cashless Basis FairValueOfWarrantsExercisedOnACashlessBasis	0	USD
CY2014Q4	abus	Fair Value Of Warrants Outstanding Per Warrant FairValueOfWarrantsOutstandingPerWarrant	12.80
CY2015Q4	abus	Fair Value Of Warrants Outstanding Per Warrant FairValueOfWarrantsOutstandingPerWarrant	2.33
CY2013	abus	Fair Value Warrants Foreign Exchange Gain Loss FairValueWarrantsForeignExchangeGainLoss	-312000	USD
CY2014	abus	Fair Value Warrants Foreign Exchange Gain Loss FairValueWarrantsForeignExchangeGainLoss	-455000	USD
CY2015	abus	Fair Value Warrants Foreign Exchange Gain Loss FairValueWarrantsForeignExchangeGainLoss	-541000	USD
CY2013	abus	Increase Decrease In Fair Value Of Contingent Consideration Liability IncreaseDecreaseInFairValueOfContingentConsiderationLiability	0	USD
CY2014	abus	Increase Decrease In Fair Value Of Contingent Consideration Liability IncreaseDecreaseInFairValueOfContingentConsiderationLiability	0	USD
CY2015	abus	Increase Decrease In Fair Value Of Contingent Consideration Liability IncreaseDecreaseInFairValueOfContingentConsiderationLiability	770000	USD
CY2013	abus	Increase Decrease In Value Of Warrants IncreaseDecreaseInValueOfWarrants	3530000	USD
CY2014	abus	Increase Decrease In Value Of Warrants IncreaseDecreaseInValueOfWarrants	10383000	USD
CY2015	abus	Increase Decrease In Value Of Warrants IncreaseDecreaseInValueOfWarrants	-3341000	USD
CY2013	abus	Increase Decrease Other Deferred Costs Net IncreaseDecreaseOtherDeferredCostsNet	-231000	USD
CY2014	abus	Increase Decrease Other Deferred Costs Net IncreaseDecreaseOtherDeferredCostsNet	-167000	USD
CY2015	abus	Increase Decrease Other Deferred Costs Net IncreaseDecreaseOtherDeferredCostsNet	0	USD
CY2015Q4	abus	Market Capitalization Value MarketCapitalizationValue	242844000	USD
	abus	Maximum Contribution For Product MaximumContributionForProduct	7179000	USD
	abus	Maximum Contribution For Product MaximumContributionForProduct	9330000	CAD
CY2014Q4	abus	Net Liquidity NetLiquidity	102833000	USD
CY2015Q4	abus	Net Liquidity NetLiquidity	172477000	USD
CY2014Q1	abus	Number Of Additional Shares Authorized NumberOfAdditionalSharesAuthorized	318750	shares
CY2006Q2	abus	Number Of Chemotherapy Products With Worldwide Licenses NumberOfChemotherapyProductsWithWorldwideLicenses	3	chemotherapy_products
CY2013Q4	abus	Number Of Executive Officers Granted Options With New Appointments NumberOfExecutiveOfficersGrantedOptionsWithNewAppointments	2	executive_officers
CY2015Q4	abus	Numberof Share Based Compensation Plans NumberofShareBasedCompensationPlans	6	compensation_plan
CY2013	abus	Opening Liability Of Warrants Issued In The Period OpeningLiabilityOfWarrantsIssuedInThePeriod	0	USD
CY2014	abus	Opening Liability Of Warrants Issued In The Period OpeningLiabilityOfWarrantsIssuedInThePeriod	0	USD
CY2015	abus	Opening Liability Of Warrants Issued In The Period OpeningLiabilityOfWarrantsIssuedInThePeriod	0	USD
CY2011Q4	abus	Patent Tax Refund Percentage PatentTaxRefundPercentage	0.75
	abus	Percent Of Costs Funded By Tpc PercentOfCostsFundedByTPC	0.27
CY2014Q1	abus	Potential Proceeds Of Additional Shares Authorized PotentialProceedsOfAdditionalSharesAuthorized	9084000	USD
CY2015Q1	abus	Potential Proceeds Of Additional Shares Authorized PotentialProceedsOfAdditionalSharesAuthorized	22781000	USD
CY2013Q4	abus	Proceeds From Issuance Of Common Stock Net ProceedsFromIssuanceOfCommonStockNet	32038000	USD
CY2014Q1	abus	Proceeds From Issuance Of Common Stock Net ProceedsFromIssuanceOfCommonStockNet	56477000	USD
CY2015Q1	abus	Proceeds From Issuance Of Common Stock Net ProceedsFromIssuanceOfCommonStockNet	142177000	USD
CY2015	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	9656000	USD
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	770000	USD
CY2015	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2014Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	9328000	USD
CY2015	abus	Royalty Guarantees Commitments Percentage RoyaltyGuaranteesCommitmentsPercentage	0.025
CY2014Q4	abus	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Options Nonvested Weighted Average Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsNonvestedWeightedAverageFairValue	9.30
CY2014Q4	abus	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Options Nonvested Weighted Average Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsNonvestedWeightedAverageFairValue	8.42
CY2015Q4	abus	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Options Nonvested Weighted Average Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsNonvestedWeightedAverageFairValue	11.34
CY2015Q4	abus	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Options Nonvested Weighted Average Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsNonvestedWeightedAverageFairValue	15.69
CY2015	abus	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Options Vested In Period Weighted Average Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsVestedInPeriodWeightedAverageFairValue	8.77
CY2015	abus	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Options Vested In Period Weighted Average Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsVestedInPeriodWeightedAverageFairValue	6.86
CY2014	abus	Warrants Exercised WarrantsExercised	610478	shares
CY2015	abus	Warrants Exercised WarrantsExercised	18750	shares
CY2015Q4	abus	Wholly Owned Subsidiaries Includedin Financial Statements WhollyOwnedSubsidiariesIncludedinFinancialStatements	4	subsidiary
CY2015	dei	Amendment Flag AmendmentFlag	false
CY2015	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2015	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2015	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2015
CY2015	dei	Document Period End Date DocumentPeriodEndDate	2015-12-31
CY2015	dei	Document Type DocumentType	10-K
CY2015	dei	Entity Central Index Key EntityCentralIndexKey	0001447028
CY2016Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	54625703	shares
CY2015	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2015	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2015Q2	dei	Entity Public Float EntityPublicFloat	644038348	USD
CY2015	dei	Entity Registrant Name EntityRegistrantName	Arbutus Biopharma Corp
CY2015	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2015Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	8827000	USD
CY2014Q4	us-gaap	Accounts Payable And Accrued Liabilities Current And Noncurrent AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent	9328000	USD
CY2015Q4	us-gaap	Accounts Payable And Accrued Liabilities Current And Noncurrent AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent	8827000	USD
CY2014Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	2044000	USD
CY2015Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	2610000	USD
CY2014Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	1903000	USD
CY2015Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	1008000	USD
CY2014Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1903000	USD
CY2015Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1008000	USD
CY2014Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1294000	USD
CY2015Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	640000	USD
CY2014Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	11199000	USD
CY2015Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	9729000	USD
CY2014Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-22313000	USD
CY2015Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-49782000	USD
CY2014Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	26208000	USD
CY2015Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	30206000	USD
CY2013	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	903000	USD
CY2014	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3283000	USD
CY2015	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	22093000	USD
CY2014Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	112161000	USD
CY2015Q4	us-gaap	Assets Assets	712291000	USD
CY2014Q4	us-gaap	Assets Current AssetsCurrent	116418000	USD
CY2015Q4	us-gaap	Assets Current AssetsCurrent	183882000	USD
CY2013	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	2462000	USD
CY2014	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	4085000	USD
CY2015	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	9700000	USD
CY2013	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3064767	shares
CY2014	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2221233	shares
CY2015	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2899331	shares
CY2015	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	USD
CY2014Q4	us-gaap	Assets Assets	118178000	USD
CY2015Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	191374000	USD
CY2014	us-gaap	Business Acquisitions Pro Forma Income Loss From Continuing Operations Before Changes In Accounting And Extraordinary Items Net Of Tax BusinessAcquisitionsProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTax	-51088000	USD
CY2015	us-gaap	Business Acquisitions Pro Forma Income Loss From Continuing Operations Before Changes In Accounting And Extraordinary Items Net Of Tax BusinessAcquisitionsProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTax	-109387000	USD
CY2014	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	-56491000	USD
CY2015	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	-67416000	USD
CY2014	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	14953000	USD
CY2015	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	24873000	USD
CY2013	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	0	USD
CY2014	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	462000	USD
CY2013	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	0	USD
CY2014	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	0	USD
CY2015	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	770000	USD
CY2014Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	0	USD
CY2015Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	7497000	USD
CY2015Q1	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	6727000	USD
CY2013	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	0	USD
CY2014	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	0	USD
CY2015	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	324000	USD
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	47024000	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	68717000	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	72187000	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	166779000	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	72187000	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	166779000	USD
CY2013	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	21693000	USD
CY2014	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	3470000	USD
CY2015	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	94592000	USD
CY2014Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	112161000	USD
CY2015Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	181304000	USD
CY2013Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	2.90
CY2013Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	2.72
CY2014Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	2.67
CY2014Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	2.95
CY2015Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	2.13
CY2015Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	2.95
CY2013Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	1014728	shares
CY2014Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	398250	shares
CY2015Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	379500	shares
CY2014Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	398250	shares
CY2015Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	379500	shares
CY2014Q4	us-gaap	Common Stock No Par Value CommonStockNoParValue	0
CY2015Q4	us-gaap	Common Stock No Par Value CommonStockNoParValue	0
CY2014Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	22438169	shares
CY2015Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	54570691	shares
CY2014Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	22438169	shares
CY2015Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	54570691	shares
CY2014Q4	us-gaap	Common Stock Value CommonStockValue	290004000	USD
CY2015Q4	us-gaap	Common Stock Value CommonStockValue	834240000	USD
CY2013	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-17198000	USD
CY2014	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-45326000	USD
CY2015	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-88590000	USD
CY2013	us-gaap	Contracts Revenue ContractsRevenue	10425000	USD
CY2014	us-gaap	Contracts Revenue ContractsRevenue	11738000	USD
CY2015	us-gaap	Contracts Revenue ContractsRevenue	13309000	USD
CY2013	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	USD
CY2014	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	USD
CY2015	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-16185000	USD
CY2015Q4	us-gaap	Deferred Revenue DeferredRevenue	1081000	USD
CY2014Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	5779000	USD
CY2015Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	146324000	USD
CY2014Q4	us-gaap	Deferred Tax Liabilities Deferred Expense Capitalized Research And Development Costs DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts	0	USD
CY2015Q4	us-gaap	Deferred Tax Liabilities Deferred Expense Capitalized Research And Development Costs DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts	146324000	USD
CY2014Q4	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	0	USD
CY2015Q4	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	146324000	USD
CY2015Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	104830000	USD
CY2014Q4	us-gaap	Deferred Revenue DeferredRevenue	15716000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	37818000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	41494000	USD
CY2013	us-gaap	Depreciation Depreciation	613000	USD
CY2014	us-gaap	Depreciation Depreciation	529000	USD
CY2015	us-gaap	Depreciation Depreciation	589000	USD
CY2013	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.92
CY2014	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.80
CY2015	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.34
CY2014Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1195000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	777000	USD
CY2015Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	868000	USD
CY2014Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	9937000	USD
CY2015Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	213000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	37818000	USD
CY2014Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	14006000	USD
CY2015Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	13474000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	USD
CY2014Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	6578000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	13932000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Subject To Expiration DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration	17235000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	483000	USD
CY2014Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.91
CY2014Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.28
CY2014Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.39
CY2014Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.27
CY2014	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.80
CY2015Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.40
CY2015Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.27
CY2015Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.57
CY2015Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.10
CY2015	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.34
CY2013	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.92
CY2014	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.80
CY2015	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.34
CY2013	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-3561000	USD
CY2014	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-1827000	USD
CY2015	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-2175000	USD
CY2013	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.26
CY2014	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.26
CY2015	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.26
CY2015Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	11972000	USD
CY2015	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P16M
CY2013	us-gaap	Employee Stock Ownership Plan Esop Compensation Expense EmployeeStockOwnershipPlanESOPCompensationExpense	903000	USD
CY2014	us-gaap	Employee Stock Ownership Plan Esop Compensation Expense EmployeeStockOwnershipPlanESOPCompensationExpense	3283000	USD
CY2015	us-gaap	Employee Stock Ownership Plan Esop Compensation Expense EmployeeStockOwnershipPlanESOPCompensationExpense	22093000	USD
CY2014	us-gaap	Fair Value Assumptions Expected Dividend Rate FairValueAssumptionsExpectedDividendRate	0
CY2015	us-gaap	Fair Value Assumptions Expected Dividend Rate FairValueAssumptionsExpectedDividendRate	0
CY2014	us-gaap	Fair Value Assumptions Expected Term FairValueAssumptionsExpectedTerm	P6M
CY2015	us-gaap	Fair Value Assumptions Expected Term FairValueAssumptionsExpectedTerm	P7M6D
CY2014	us-gaap	Fair Value Assumptions Expected Volatility Rate FairValueAssumptionsExpectedVolatilityRate	0.8522
CY2015	us-gaap	Fair Value Assumptions Expected Volatility Rate FairValueAssumptionsExpectedVolatilityRate	0.4907
CY2014	us-gaap	Fair Value Assumptions Risk Free Interest Rate FairValueAssumptionsRiskFreeInterestRate	0.01
CY2015	us-gaap	Fair Value Assumptions Risk Free Interest Rate FairValueAssumptionsRiskFreeInterestRate	0.0048
CY2014Q4	us-gaap	Fair Value Concentration Of Risk Derivative Financial Instruments Liabilities FairValueConcentrationOfRiskDerivativeFinancialInstrumentsLiabilities	0	USD
CY2015Q4	us-gaap	Fair Value Concentration Of Risk Derivative Financial Instruments Liabilities FairValueConcentrationOfRiskDerivativeFinancialInstrumentsLiabilities	0	USD
CY2013	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	-3530000	USD
CY2014	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	-10383000	USD
CY2015	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	3341000	USD
CY2013	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	1079000	USD
CY2014	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	4127000	USD
CY2015	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	21771000	USD
CY2013	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	18000	USD
CY2014	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	4218000	USD
CY2015	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	21966000	USD
CY2013	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	USD
CY2014	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	80000	USD
CY2015	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	USD
CY2013	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5546000	USD
CY2014	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8683000	USD
CY2015	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	26438000	USD
CY2014Q4	us-gaap	Goodwill Goodwill	0	USD
CY2015Q4	us-gaap	Goodwill Goodwill	162514000	USD
CY2013	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	0	USD
CY2014	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	0	USD
CY2015	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	39007000	USD
CY2013	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-14063000	USD
CY2014	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-38837000	USD
CY2015	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-77306000	USD
CY2013	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2014	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2015	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-16185000	USD
CY2013	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	2407000	USD
CY2014	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	6599000	USD
CY2015	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	3676000	USD
CY2013	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	-9000	USD
CY2014	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	0	USD
CY2014	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1887000	USD
CY2015	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-628000	USD
CY2013	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-153000	USD
CY2014	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	13171000	USD
CY2015	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-13090000	USD
CY2013	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	31000	USD
CY2014	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	52000	USD
CY2015	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	188000	USD
CY2013	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	776000	USD
CY2015	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	0	USD
CY2013	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	0	USD
CY2014	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	0	USD
CY2015	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	-7874000	USD
CY2013	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-3486000	USD
CY2014	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-10097000	USD
CY2015	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-20100000	USD
CY2013	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	1088000	USD
CY2014	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	3498000	USD
CY2015	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	8113000	USD
CY2014Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	86000	USD
CY2015Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	246000	USD
CY2013	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	130000	USD
CY2014	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	6253000	USD
CY2015	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-2489000	USD
CY2013	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-889000	USD
CY2014	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	773000	USD
CY2015	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-159000	USD
CY2013	us-gaap	Increase Decrease In Unbilled Receivables IncreaseDecreaseInUnbilledReceivables	-2008000	USD
CY2014	us-gaap	Increase Decrease In Unbilled Receivables IncreaseDecreaseInUnbilledReceivables	360000	USD
CY2015	us-gaap	Increase Decrease In Unbilled Receivables IncreaseDecreaseInUnbilledReceivables	-349000	USD
CY2014Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	0	USD
CY2015Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	352642000	USD
CY2013	us-gaap	Investment Income Interest InvestmentIncomeInterest	540000	USD
CY2014	us-gaap	Investment Income Interest InvestmentIncomeInterest	853000	USD
CY2015	us-gaap	Investment Income Interest InvestmentIncomeInterest	674000	USD
CY2014	us-gaap	Investment Tax Credit InvestmentTaxCredit	52000	USD
CY2015	us-gaap	Investment Tax Credit InvestmentTaxCredit	196000	USD
CY2014Q4	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	39974000	USD
CY2015Q4	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	14525000	USD
CY2014Q4	us-gaap	Lease Incentive Payable Current LeaseIncentivePayableCurrent	250000	USD
CY2015Q4	us-gaap	Lease Incentive Payable Current LeaseIncentivePayableCurrent	297000	USD
CY2014Q4	us-gaap	Liabilities Liabilities	30143000	USD
CY2015Q4	us-gaap	Liabilities Liabilities	164612000	USD
CY2014Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	118178000	USD
CY2015Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	712291000	USD
CY2014Q4	us-gaap	Liabilities Current LiabilitiesCurrent	20206000	USD
CY2015Q4	us-gaap	Liabilities Current LiabilitiesCurrent	10578000	USD
CY2014Q4	us-gaap	Liabilities Fair Value Disclosure Recurring LiabilitiesFairValueDisclosureRecurring	5099000	USD
CY2015Q4	us-gaap	Liabilities Fair Value Disclosure Recurring LiabilitiesFairValueDisclosureRecurring	8380000	USD
CY2013	us-gaap	Licenses Revenue LicensesRevenue	5040000	USD
CY2014	us-gaap	Licenses Revenue LicensesRevenue	3215000	USD
CY2015	us-gaap	Licenses Revenue LicensesRevenue	11564000	USD
CY2014Q4	us-gaap	Long Term Investments LongTermInvestments	0	USD
CY2015Q4	us-gaap	Long Term Investments LongTermInvestments	10070000	USD
CY2013	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	32716000	USD
CY2014	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	60676000	USD
CY2015	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	143870000	USD
CY2013	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-725000	USD
CY2014	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-42958000	USD
CY2015	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	7682000	USD
CY2013	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6737000	USD
CY2014	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-12421000	USD
CY2015	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-54785000	USD
CY2013	us-gaap	Net Income Loss NetIncomeLoss	-14063000	USD
CY2014Q1	us-gaap	Net Income Loss NetIncomeLoss	-17984000	USD
CY2014Q2	us-gaap	Net Income Loss NetIncomeLoss	-6081000	USD
CY2014Q3	us-gaap	Net Income Loss NetIncomeLoss	-8604000	USD
CY2014Q4	us-gaap	Net Income Loss NetIncomeLoss	-6168000	USD
CY2014	us-gaap	Net Income Loss NetIncomeLoss	-38837000	USD
CY2015Q1	us-gaap	Net Income Loss NetIncomeLoss	-11989000	USD
CY2015Q2	us-gaap	Net Income Loss NetIncomeLoss	-14886000	USD
CY2015Q3	us-gaap	Net Income Loss NetIncomeLoss	-28982000	USD
CY2015Q4	us-gaap	Net Income Loss NetIncomeLoss	-5264000	USD
CY2015	us-gaap	Net Income Loss NetIncomeLoss	-61121000	USD
CY2013	us-gaap	Noncash Or Part Noncash Acquisition Net Nonmonetary Assets Acquired Liabilities Assumed1 NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1	0	USD
CY2014	us-gaap	Noncash Or Part Noncash Acquisition Net Nonmonetary Assets Acquired Liabilities Assumed1 NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1	0	USD
CY2015	us-gaap	Noncash Or Part Noncash Acquisition Net Nonmonetary Assets Acquired Liabilities Assumed1 NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1	381618000	USD
CY2013	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1911000	USD
CY2014	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-5403000	USD
CY2015	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	25016000	USD
CY2015	us-gaap	Number Of Reporting Units NumberOfReportingUnits	1	reporting_unit
CY2013	us-gaap	Operating Expenses OperatingExpenses	27617000	USD
CY2014	us-gaap	Operating Expenses OperatingExpenses	48387000	USD
CY2015	us-gaap	Operating Expenses OperatingExpenses	127195000	USD
CY2013	us-gaap	Operating Income Loss OperatingIncomeLoss	-12152000	USD
CY2014Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-5958000	USD
CY2014Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-9423000	USD
CY2014Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-6844000	USD
CY2014Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-10747000	USD
CY2014	us-gaap	Operating Income Loss OperatingIncomeLoss	-33434000	USD
CY2015Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-18006000	USD
CY2015Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-14420000	USD
CY2015Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-58138000	USD
CY2015Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-11758000	USD
CY2015	us-gaap	Operating Income Loss OperatingIncomeLoss	-102322000	USD
CY2015Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	3652000	USD
CY2015Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	1229000	USD
CY2015Q4	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	547000	USD
CY2015Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	938000	USD
CY2015Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	938000	USD
CY2013	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	1225000	USD
CY2014	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	1133000	USD
CY2015	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	1158000	USD
CY2014Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	226000	USD
CY2015Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	591000	USD
CY2013	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-3135000	USD
CY2014	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-6489000	USD
CY2015	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-27469000	USD
CY2013	us-gaap	Payments For Proceeds From Investments PaymentsForProceedsFromInvestments	0	USD
CY2014	us-gaap	Payments For Proceeds From Investments PaymentsForProceedsFromInvestments	41982000	USD
CY2015	us-gaap	Payments For Proceeds From Investments PaymentsForProceedsFromInvestments	-9645000	USD
CY2013Q4	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	2462000	USD
CY2014Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	4085000	USD
CY2015Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	9700000	USD
CY2013	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	725000	USD
CY2014	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1056000	USD
CY2015	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2287000	USD
CY2014Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1730000	USD
CY2015Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1196000	USD
CY2013	us-gaap	Proceeds From Income Tax Refunds ProceedsFromIncomeTaxRefunds	10000	USD
CY2014	us-gaap	Proceeds From Income Tax Refunds ProceedsFromIncomeTaxRefunds	0	USD
CY2015	us-gaap	Proceeds From Income Tax Refunds ProceedsFromIncomeTaxRefunds	24000	USD
CY2013Q4	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	34500000	USD
CY2013Q4	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	30000000	USD
CY2014Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	60562000	USD
CY2015Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	151875000	USD
CY2013	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	32038000	USD
CY2014	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	56477000	USD
CY2015	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	142177000	USD
CY2013	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	USD
CY2014	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	80000	USD
CY2015	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	USD
CY2013	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	389000	USD
CY2014	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	2616000	USD
CY2015	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1651000	USD
CY2013	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	289000	USD
CY2014	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	1583000	USD
CY2015	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	42000	USD
CY2014Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	12959000	USD
CY2013	us-gaap	Revenues Revenues	15465000	USD
CY2014Q1	us-gaap	Revenues Revenues	4430000	USD
CY2014Q2	us-gaap	Revenues Revenues	1811000	USD
CY2014Q3	us-gaap	Revenues Revenues	4362000	USD
CY2014Q4	us-gaap	Revenues Revenues	4350000	USD
CY2014	us-gaap	Revenues Revenues	14953000	USD
CY2015Q1	us-gaap	Revenues Revenues	4682000	USD
CY2015Q2	us-gaap	Revenues Revenues	3440000	USD
CY2015Q3	us-gaap	Revenues Revenues	4065000	USD
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1309625	shares
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	15.20
CY2015Q4	us-gaap	Revenues Revenues	12686000	USD
CY2015	us-gaap	Revenues Revenues	24873000	USD
CY2015Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	12912000	USD
CY2014Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1760000	USD
CY2015Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3183000	USD
CY2013	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	21458000	USD
CY2014	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	38713000	USD
CY2015	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	51505000	USD
CY2014Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-205864000	USD
CY2015Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-266985000	USD
CY2014	us-gaap	Revenue From Grants RevenueFromGrants	172000	USD
CY2013Q4	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	8.00
CY2013Q4	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	8.00
CY2014Q1	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	28.50
CY2015	us-gaap	Revenue From Grants RevenueFromGrants	1245000	USD
CY2015Q4	us-gaap	Short Term Investments ShortTermInvestments	14525000	USD
CY2014	us-gaap	Stock Issued During Period Shares Conversion Of Convertible Securities StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities	5285	shares
CY2013Q4	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	562500	shares
CY2015Q1	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	20.25
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	3135980	shares
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	800000	shares
CY2015Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	3500000	shares
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1377091	shares
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1088908	shares
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	938730	shares
CY2015Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1125000	shares
CY2015	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	1718000	USD
CY2015	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	250461	shares
CY2015	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2	P6Y1M6D
CY2014Q4	us-gaap	Short Term Investments ShortTermInvestments	39974000	USD
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	11.89
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2519831	shares
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	943000	USD
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	2626000	USD
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	10000	USD
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	15.54
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	21.51
CY2015	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	11.16
CY2015	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	14.27
CY2014Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod	P30D
CY2015Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod	P30D
CY2015Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	994000	USD
CY2014Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	441230	shares
CY2015Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	1351541	shares
CY2015	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares	148853	shares
CY2015	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P9Y1M6D
CY2013	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	955000	USD
CY2014	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	2505000	USD
CY2013Q4	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	3750000	shares
CY2014Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	2125000	shares
CY2015Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	7500000	shares
CY2015	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	381942000	USD
CY2013	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	32038000	USD
CY2014	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	56477000	USD
CY2015	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	142177000	USD
CY2013	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	2143000	USD
CY2014	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	11791000	USD
CY2015	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	371000	USD
CY2013	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	389000	USD
CY2014	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	2616000	USD
CY2015	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1651000	USD
CY2012Q4	us-gaap	Stockholders Equity StockholdersEquity	40919000	USD
CY2013Q4	us-gaap	Stockholders Equity StockholdersEquity	59194000	USD
CY2014Q4	us-gaap	Stockholders Equity StockholdersEquity	88035000	USD
CY2015Q4	us-gaap	Stockholders Equity StockholdersEquity	547679000	USD
CY2014Q4	us-gaap	Unbilled Receivables Current UnbilledReceivablesCurrent	538000	USD
CY2015Q4	us-gaap	Unbilled Receivables Current UnbilledReceivablesCurrent	128000	USD
CY2014Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	5099000	USD
CY2015Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	883000	USD
CY2012Q4	us-gaap	Warrants Not Settleable In Cash Fair Value Disclosure WarrantsNotSettleableInCashFairValueDisclosure	4015000	USD
CY2013Q4	us-gaap	Warrants Not Settleable In Cash Fair Value Disclosure WarrantsNotSettleableInCashFairValueDisclosure	5379000	USD
CY2014Q4	us-gaap	Warrants Not Settleable In Cash Fair Value Disclosure WarrantsNotSettleableInCashFairValueDisclosure	5099000	USD
CY2015Q4	us-gaap	Warrants Not Settleable In Cash Fair Value Disclosure WarrantsNotSettleableInCashFairValueDisclosure	883000	USD
CY2013	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	15302680	shares
CY2014	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	21603136	shares
CY2015	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	45462324	shares
CY2013	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	15302680	shares
CY2014	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	21603136	shares
CY2015	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	45462324	shares
CY2015	us-gaap	Nature Of Operations NatureOfOperations	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Nature of business and future operations</font></div><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Arbutus Biopharma Corporation (the “Company” or “Arbutus”) is a Canadian biopharmaceutical business dedicated to discovering, developing, and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV), a disease of the liver caused by the hepatitis B virus (“HBV”). The Company is also developing a pipeline focused on advancing novel RNA interference therapeutics (RNAi) leveraging the Company’s expertise in Lipid Nanoparticle (LNP) technology.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Effective July 31, 2015, the corporate name changed from Tekmira Pharmaceuticals Corporation (Tekmira) to Arbutus Biopharma Corporation. Also effective July 31, 2015, the corporate name of the wholly-owned subsidiary, OnCore Biopharma, Inc. (OnCore) changed to Arbutus Biopharma, Inc. (Arbutus Inc.). Including Arbutus Inc., the Company has </font><font style="font-family:inherit;font-size:10pt;">four</font><font style="font-family:inherit;font-size:10pt;"> wholly-owned subsidiaries: Protiva Biotherapeutics Inc. (Protiva), Protiva Biotherapeutics (USA) Inc. (Protiva USA), and Protiva Agricultural Development Company Inc. (“PADCo”). In March 2016, Monsanto exercised its option to acquire 100% of the outstanding shares in PADCo - refer to note 13 subsequent events.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The success of the Company is dependent on obtaining the necessary regulatory approvals to bring its products to market and achieve profitable operations. The continuation of the research and development activities and the commercialization of its products are dependent on the Company’s ability to successfully complete these activities and to obtain adequate financing through a combination of financing activities and operations. It is not possible to predict either the outcome of future research and development programs or the Company’s ability to continue to fund these programs in the future.</font></div></div>
CY2015	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of estimates</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of the consolidated financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions about future events that affect the reported amounts of assets, liabilities, revenue, expenses, contingent assets and contingent liabilities as at the end or during the reporting period. Actual results could significantly differ from those estimates. Significant areas requiring the use of management estimates relate to purchase price allocation, valuation of intangible assets and goodwill, recognition of revenue, stock-based compensation, valuation of warrant liability and financial instrument, and the amounts recorded as accrued liabilities, contingent consideration, and income tax recovery.</font></div></div>

Files In Submission

Name	View Source	Status
0001628280-16-012462-index-headers.html	Edgar Link	pending
0001628280-16-012462-index.html	Edgar Link	pending
0001628280-16-012462.txt	Edgar Link	pending
0001628280-16-012462-xbrl.zip	Edgar Link	pending
abus-20151231.xml	Edgar Link	completed
abus-20151231.xsd	Edgar Link	pending
abus-20151231_cal.xml	Edgar Link	unprocessable
abus-20151231_def.xml	Edgar Link	unprocessable
abus-20151231_lab.xml	Edgar Link	unprocessable
abus-20151231_pre.xml	Edgar Link	unprocessable
arb1467phase2design.jpg	Edgar Link	pending
arb1467triggers.jpg	Edgar Link	pending
arbutus10k2015.htm	Edgar Link	pending
arbutus10k2_chart-35315.jpg	Edgar Link	pending
exhibit1078lizhowardea.htm	Edgar Link	pending
exhibit1079monsantoamendme.htm	Edgar Link	pending
exhibit1080monsantoamendme.htm	Edgar Link	pending
exhibit1081monsantoamendme.htm	Edgar Link	pending
exhibit211listingofsubsidi.htm	Edgar Link	pending
exhibit231kpmgconsent.htm	Edgar Link	pending
exhibit311.htm	Edgar Link	pending
exhibit312.htm	Edgar Link	pending
exhibit321.htm	Edgar Link	pending
exhibit322.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
hbvlifecycle.jpg	Edgar Link	pending
hbvpipeline.jpg	Edgar Link	pending
lnptechnology.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ABUS
Arbutus Biopharma Corp Stock $abus

2016 Q1 Form 10-K Financial Statement

#000162828016012462 Filed on March 09, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ABUS Arbutus Biopharma Corp Stock $abus

2016 Q1 Form 10-K Financial Statement

#000162828016012462 Filed on March 09, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ABUS
Arbutus Biopharma Corp Stock $abus